DOYLESTOWN, PA — Aprea Therapeutics Inc. (Nasdaq: APRE) will put its clinical-stage cancer drug pipeline before investors at the H.C. Wainwright Global Investment Conference Sept. 14-16 as the company advances two targeted therapies for solid tumors.
President and Chief Executive Officer Oren Gilad is scheduled to present at the conference, which will be held in person and virtually.
Aprea’s lead programs are APR-1051, an oral small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small-molecule ATR inhibitor. Both are in clinical development for solid tumor indications.
The company is developing targeted therapies for patients with biomarker-defined cancers by exploiting vulnerabilities associated with cancer-cell mutations. Its technology has potential applications in ovarian, colorectal, prostate and breast cancers.
A webcast of Gilad’s presentation is available at https://journey.ct.events/view/4a53715f-1804-430d-8179-3d35f88f1106.
Investors can register for the conference at https://hcwevents.com/annualconference/. Those seeking one-on-one meetings with Aprea management can contact their H.C. Wainwright representative.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.